Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $10.0 million.

  • Arcutis Biotherapeutics' Share-based Compensation rose 258.59% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.7 million, marking a year-over-year decrease of 339.95%. This contributed to the annual value of $41.7 million for FY2024, which is 751.55% up from last year.
  • Arcutis Biotherapeutics' Share-based Compensation amounted to $10.0 million in Q3 2025, which was up 258.59% from $10.5 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Share-based Compensation's 5-year high stood at $12.5 million during Q2 2024, with a 5-year trough of $4.3 million in Q2 2021.
  • For the 5-year period, Arcutis Biotherapeutics' Share-based Compensation averaged around $8.8 million, with its median value being $9.4 million (2024).
  • Per our database at Business Quant, Arcutis Biotherapeutics' Share-based Compensation soared by 75888.89% in 2021 and then tumbled by 2316.83% in 2022.
  • Arcutis Biotherapeutics' Share-based Compensation (Quarter) stood at $5.7 million in 2021, then skyrocketed by 62.93% to $9.3 million in 2022, then decreased by 5.47% to $8.8 million in 2023, then grew by 7.26% to $9.4 million in 2024, then increased by 6.86% to $10.0 million in 2025.
  • Its Share-based Compensation was $10.0 million in Q3 2025, compared to $10.5 million in Q2 2025 and $9.8 million in Q1 2025.